Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 20...
Main Authors: | Binwei Lin MM, Jinjia Fan MM, Fang Liu MD, Yixue Wen MM, Jie Li MD, Feng Gao MD, Yu Zhang MD, Gang Feng MM, Xiaobo Du MD, Wenzhi Chen MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-11-01
|
Series: | Technology in Cancer Research & Treatment |
Online Access: | https://doi.org/10.1177/15330338231218152 |
Similar Items
-
Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis
by: Yunzhao Luo MM, et al.
Published: (2023-01-01) -
Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer
by: Xuan Yang, MM, et al.
Published: (2022-06-01) -
Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01) -
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
by: M. C. Liefaard, et al.
Published: (2024-04-01) -
Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland
by: Agnieszka Irena Jagiełło-Gruszfeld, et al.
Published: (2022-02-01)